Clinical Trial Update: Compassionate Use for BIA 28-6156 in Patients With Parkinson's Disease (PD) Who Have a Pathogenic Variant in the GBA1 Gene (GBA-PD) and Completed the ACTIVATE Study

View source ↗

Summary

This clinical-trial update describes compassionate-use access to BIA 28-6156 for Parkinson disease patients with pathogenic GBA1 variants who completed the ACTI…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• BIA 28-6156

Snippet

Sponsor: Bial R&D Investments, S.A. | Conditions: Parkinson Disease | Status: AVAILABLE